2023年ESMO妇科肿瘤治疗最新进展及展望

doi:10.19401/j.cnki.1007-3639.2023.11.001

中国癌症杂志 ›› 2023, Vol. 33 ›› Issue (11): 969-980.doi: 10.19401/j.cnki.1007-3639.2023.11.001

2023年ESMO妇科肿瘤治疗最新进展及展望

夏玲芳¹^,²(), 朱俊¹^,², 吴小华¹^,²()

复旦大学附属肿瘤医院妇瘤科，复旦大学上海医学院肿瘤学系，上海 200032

收稿日期:2023-11-10 修回日期:2023-11-15 出版日期:2023-11-30 发布日期:2023-12-14
通信作者: 吴小华（ORCID: 0000-0002-2271-2514），博士，主任医师，复旦大学附属肿瘤医院妇瘤科主任。
作者简介:夏玲芳（ORCID: 0000-0002-4423-1615），博士，副主任医师。
吴小华，医学博士，主任医师，教授，博士研究生导师。现任复旦大学附属肿瘤医院妇瘤科主任、妇科肿瘤多学科综合治疗组首席专家，上海市优秀学科带头人，上海市医学领军人才。现任中国抗癌协会卵巢癌专业委员会主任委员、中国初级卫生保健基金会妇科专业委员会主任委员、中国临床肿瘤学会理事、上海市抗癌协会常务理事、中国抗癌协会妇科肿瘤专业委员会前任主任委员及上海市抗癌协会妇科肿瘤专业委员会前任主任委员。曾任国际妇科癌症学会教育委员会委员、亚太地区理事候选人、美国妇科肿瘤学会国际委员会委员、美国西北大学Feinberg医学院妇产科学系兼职教授等。目前还担任International Journal of Gynecological Cancer、Cancer Medicine、Journal of Gynecological Oncology等英文杂志和《中华妇产科杂志》《中华解剖与临床杂志》《中国癌症杂志》等中文杂志编委，美国国立综合癌症网络（National Comprehensive Cancer Network，NCCN）妇科肿瘤临床指南国际审阅专家。

The latest progress and prospect of gynecological tumor treatment at 2023 ESMO

XIA Lingfang¹^,²(), ZHU Jun¹^,², WU Xiaohua¹^,²()

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Received:2023-11-10 Revised:2023-11-15 Published:2023-11-30 Online:2023-12-14

摘要/Abstract

摘要：

妇科肿瘤（宫颈癌、卵巢癌和子宫内膜癌）领域在过去1年取得了诸多重磅性研究成果，包括手术治疗方式、局部晚期治疗模式及复发转移的新治疗探索等，尤其是免疫治疗、靶向治疗和抗体药物偶联物（antibody-drug conjugate，ADC）治疗等新兴治疗方式相较于传统的治疗模式，其研究开创了治疗的新纪元，为患者带来更多的治疗希望。本文总结2023年欧洲肿瘤内科学会（European Society for Medical Oncology，ESMO）年会中妇科肿瘤在手术治疗、放疗、化疗及新型靶向免疫治疗等方面的重大进展，以期更好地指导临床个体化精准治疗。

关键词: 宫颈癌, 卵巢癌, 子宫内膜癌, 免疫治疗, 靶向治疗, 抗体药物偶联物

Abstract:

Many major research achievements have been made in the past year in the field of gynecologic oncology (cervical cancer, ovarian cancer and endometrial cancer), including surgical treatment, local advanced treatment mode and exploration of new treatments for recurrence and metastasis. Especially the research of emerging treatment methods such as immunotherapy, targeted therapy and antibody-drug conjugate therapy has opened a new era of treatment and brought more hopes for treatment to patients. This paper summarizes the major advances in surgical treatment, radiotherapy, chemotherapy and novel targeted immunotherapy for gynecologic oncology at 2023 Annual Meeting of European Society for Medical Oncology (ESMO), in order to better guide the individualized precision treatment.

Key words: Cervical cancer, Ovarian cancer, Endometrial cancer, Immunotherapy, Targeted therapy, Antibody-drug conjugate

中图分类号:

R737.3

夏玲芳, 朱俊, 吴小华. 2023年ESMO妇科肿瘤治疗最新进展及展望[J]. 中国癌症杂志, 2023, 33(11): 969-980.

XIA Lingfang, ZHU Jun, WU Xiaohua. The latest progress and prospect of gynecological tumor treatment at 2023 ESMO[J]. China Oncology, 2023, 33(11): 969-980.

参考文献 35

[1]	郑荣寿, 张思维, 孙可欣, 等. 2016年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2023, 45(3): 212-220.
	ZHENG R S, ZHANG S W, SUN K X, et al. Cancer statistics in China, 2016[J]. Chin J Oncol, 2023, 45(3): 212-220.
[2]	MCCORMACK M, GALLARDO RINCÓN D, EMINOWICZ G, et al. A randomised phase Ⅲ trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: the GCIG INTERLACE trial[J]. Ann Oncol, 2023, 34: S1276.
[3]	MILESHKIN L R, MOORE K N, BARNES E H, et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2023, 24(5): 468-482. doi: 10.1016/S1470-2045(23)00147-X pmid: 37080223
[4]	LORUSSO D, XIANG Y, HASEGAWA K, et al. Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: a randomized, double-blind, phase Ⅲ ENGOT-cx11/GOG-3047/KEYNOTE-A18 study[J]. Ann Oncol, 2023, 34: S1279-S1280. doi: 10.1016/j.annonc.2023.10.032
[5]	MAYADEV J, NUNES A T, LI M, et al. CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase Ⅲ, randomized, double-blind, multicenter study[J]. Int J Gynecol Cancer, 2020, 30(7): 1065-1070. doi: 10.1136/ijgc-2019-001135
[6]	LEATH C A, DENG W, MELL L K, et al. Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: results from NRG-GY006, a phase Ⅲ randomized trial[J]. J Clin Oncol, 2023, 41(16_suppl): 5502. doi: 10.1200/JCO.2023.41.16_suppl.5502
[7]	COLOMBO N, DUBOT C, LORUSSO D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer[J]. N Engl J Med, 2021, 385(20): 1856-1867. doi: 10.1056/NEJMoa2112435
[8]	MONK B J, COLOMBO N, TEWARI K S, et al. First-line pembrolizumab+chemotherapy versus placebo+chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826[J]. J Clin Oncol, 2023: JCO2300914.
[9]	LIU N, YANG Z, TANG D, et al. Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): a single-arm, multicenter phase Ⅱ study[J]. Ann Oncol, 2023, 34: S509.
[10]	GAO X, XU N, LI Z, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial[J]. Lancet Oncol, 2023, 24(10): 1134-1146. doi: 10.1016/S1470-2045(23)00411-4 pmid: 37797632
[11]	WU X, XIA L, ZHANG K, et al. Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer[J]. Ann Oncol, 2023, 34: S1284-S1285.
[12]	LEE J Y, WU L, BOONYAPIPAT S, et al. AdvanTIG-202: phaseⅡ randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC)[J]. Ann Oncol, 2023, 34: S509-S510.
[13]	VERGOTE I B, GONZALEZ MARTIN A, FUJIWARA K, et al. InnovaTV 301/ENGOT-cx12/GOG-3057: a global, randomized, open-label, phase Ⅲ study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer[J]. Ann Oncol, 2023, 34: S1276-S1277.
[14]	XIA B, JIANG W, CHEN J, et al. Pamiparib combined with surufatinib as a neoadjuvant therapy for advanced ovarian cancer patients in the entire population: Preliminary results of a prospective, exploratory, single-arm phase Ⅱ clinical study[J]. Ann Oncol, 2023, 34: S520.
[15]	National Comprehensive Cancer Network. NCCN Guidelines for treatment of ovarian cancer, 2023 V2[EB/OL]. [2023-11-15]. https://www.nccn.org.
[16]	中国抗癌协会妇科肿瘤专业委员会, 中国抗癌协会肿瘤多学科诊疗(MDT)专业委员会, 中国医师协会肿瘤多学科诊疗专业委员会. 妇科恶性肿瘤多学科诊疗中国专家共识(2022年版)[J]. 中国癌症杂志, 2022, 32(8): 747-756. doi: 10.19401/j.cnki.1007-3639.2022.08.010
	The Society of Gynecological Cancer of China Anti-Cancer Association, Multidisciplinary Diagnosis and Treatment (MDT) Committee of China Anti-Cancer Association, Multidisciplinary Cancer Diagnosis and Treatment Committee of Chinese Medical Doctor Association. Consensus of Chinese experts on multidisciplinary team of gynecological malignant tumors (2022 edition)[J]. Chin Oncol, 2022, 32(8): 747-756. doi: 10.19401/j.cnki.1007-3639.2022.08.010
[17]	WU X H, LIU J H, WANG X B, et al. Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): a randomized, double-blind, placebo-controlled, phase 3 trial[C]. Late Breaking Abstracts. BMJ Publishing Group Ltd, 2023.
[18]	FLOOR B, TIRZA A C B, JESSICA P, et al. Real-world time to treatment discontinuation of first-line maintenance niraparib monotherapy in epithelial ovarian cancer: CHAR1ZMA study[C]. 2023 ESMO, Abs 789P.
[19]	KURTZ J E, PUJADE-LAURAINE E, OAKNIN A, et al. Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase Ⅲ ATALANTE/ENGOT-ov29 trial[J]. J Clin Oncol, 2023, 41(30): 4768-4778. doi: 10.1200/JCO.23.00529
[20]	PUJADE-LAURAINE E, FUJIWARA K, LEDERMANN J A, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study[J]. Lancet Oncol, 2021, 22(7): 1034-1046. doi: 10.1016/S1470-2045(21)00216-3
[21]	HARTER P, TRILLSCH F, OKAMOTO A, et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo)-controlled phase Ⅲ DUO-O trial[J]. J Clin Oncol, 2023, 41(17_suppl): LBA5506. doi: 10.1200/JCO.2023.41.17_suppl.LBA5506
[22]	GONZALEZ MARTIN A, RUBIO PEREZ M J, HEITZ F, et al. Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase Ⅲ trial[J]. Ann Oncol, 2023, 34: S1278-S1279. doi: 10.1016/j.annonc.2023.10.031
[23]	LIU J F, BRADY M, MATULONIS U A, et al. Overall survival (OS) outcomes from NRG-GY004, a phase Ⅲ study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)[J]. Ann Oncol, 2023, 34: S1285. doi: 10.1016/j.annonc.2023.10.039
[24]	LIU J F, BARRY W T, BIRRER M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study[J]. Lancet Oncol, 2014, 15(11): 1207-1214. doi: 10.1016/S1470-2045(14)70391-2 pmid: 25218906
[25]	WU X, LIU J, WANG L, et al. SABRINA study: a phase Ⅱ study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)[J]. Ann Oncol, 2023, 34: S521.
[26]	LEE J M. Randomized phase Ⅱ trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)[J]. Ann Oncol, 2023, 34: S511.
[27]	MOORE K N, PHILIPOVSKIY A, HARANO K, et al. Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): subgroup analysis of a first-in-human phase Ⅰ study[J]. Ann Oncol, 2023, 34: S510. doi: 10.1016/j.annonc.2023.09.1924
[28]	HOWLETT S, BERNER A M, CONNOLLY K, et al. Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients[J]. Ann Oncol, 2023, 34: S535.
[29]	DE BRUYN M, EERKENS A L, BRUMMEL K, et al. Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer[J]. Ann Oncol, 2023, 34: S508-S509.
[30]	MIRZA M R, SHARMA S, HERRSTEDT J, et al. Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial[J]. Ann Oncol, 2023, 34: S507. doi: 10.1016/j.annonc.2023.09.1919
[31]	ESKANDER R N, SILL M, MILLER A, et al. Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial[J]. Ann Oncol, 2023, 34: S1284.
[32]	NICOLETTA C. Phase Ⅲ double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: ENGOT-en7/MaNGO/AtTEnd study[C]. 2023 ESMO, Abs LBA40.
[33]	WESTIN S N, MOORE K N, CHON H S, et al. Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva±olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): results from the phase Ⅲ DUO-E/GOG-3041/ENGOT-EN10 trial[J]. Ann Oncol, 2023, 34: S1282-S1283. doi: 10.1016/j.annonc.2023.10.035
[34]	JOLY LOBBEDEZ F, LEARY A, RAY-COQUARD I L, et al. Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: the GINECO randomized phase Ⅱb UTOLA trial[J]. Ann Oncol, 2023, 34: S1283-S1284. doi: 10.1016/j.annonc.2023.10.036
[35]	POTHURI B, NAUMANN R W, MARTIN L P, et al. Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase Ⅰ dose expansion[J]. Ann Oncol, 2023, 34: S508.

2023年ESMO妇科肿瘤治疗最新进展及展望

The latest progress and prospect of gynecological tumor treatment at 2023 ESMO

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 35

相关文章 15

编辑推荐

Metrics

本文评价

[1]	康殷楠, 陈顺, 解有成, 郑英, 何昱静, 李初谊, 于晓辉. 抗体药物偶联物在HER2阳性晚期胃癌中的应用进展和展望[J]. 中国癌症杂志, 2023, 33(8): 790-800.
[2]	郑伟涛, 李涵泺, 胡康洪. TCR-T免疫治疗肿瘤：现状、挑战及展望[J]. 中国癌症杂志, 2023, 33(7): 707-716.
[3]	黄鹤, 鞠侯雨, 杨文艺, 严明, 任国欣, 胡镜宙. PD-L2在头颈部鳞状细胞癌免疫治疗预后评估中的意义[J]. 中国癌症杂志, 2023, 33(6): 613-618.
[4]	左学良, 陈志强, 董润雨, 王智雄, 蔡娟. 联合检测LDHA和PD-L1在晚期胃癌PD-1抑制剂疗效预测及预后评估中的价值[J]. 中国癌症杂志, 2023, 33(5): 460-468.
[5]	杨闻箫, 国琳玮, 凌泓, 胡欣. 基于免疫微环境特征的曲妥珠单抗与免疫治疗联合应用预测模型[J]. 中国癌症杂志, 2023, 33(5): 484-498.
[6]	王辉, 王霞, 郜意, 胥婧, 余小娟, 范芳琴, 丁焱, 康玉. 遗传性乳腺癌-卵巢癌综合征患者一级亲属接受基因筛查的现状及影响因素研究[J]. 中国癌症杂志, 2023, 33(5): 499-505.
[7]	陈君瑶, 张文涛, 刘巧, 聂建云. 老年三阴性乳腺癌患者的临床困境和系统治疗策略[J]. 中国癌症杂志, 2023, 33(5): 506-516.
[8]	吴晶, 周娟, 苏春霞. 肺癌脂肪酸代谢重编程的研究进展[J]. 中国癌症杂志, 2023, 33(5): 517-526.
[9]	中国临床肿瘤学会免疫治疗专家委员会, 上海市抗癌协会肿瘤生物治疗专业委员会. 基因重组溶瘤腺病毒治疗恶性肿瘤临床应用中国专家共识（2022年版）[J]. 中国癌症杂志, 2023, 33(5): 527-548.
[10]	蒋金玲, 周尘飞, 王超, 赵丽琴, 吴珺玮, 张俊. 2022年度胃癌研究和诊疗新进展[J]. 中国癌症杂志, 2023, 33(4): 303-314.
[11]	田熙, 徐文浩, 朱殊璇, 艾合太木江·安外尔, 宿佳琦, 叶世琪, 瞿元元, 施国海, 张海梁, 叶定伟. 2022年度肾细胞癌基础研究及临床诊疗新进展[J]. 中国癌症杂志, 2023, 33(3): 191-200.
[12]	苏春霞, 周彩存. 2022年度肺癌领域重要临床研究进展[J]. 中国癌症杂志, 2023, 33(3): 218-227.
[13]	曾铖, 张剑. 2022年度ADC在胰腺癌领域的研究新进展及展望[J]. 中国癌症杂志, 2023, 33(3): 235-240.
[14]	赵满英, 伍东月, 杜瑞亭, 尹璐, 骆玉露. METTL14介导ERα的m6A修饰调控子宫内膜癌转移的机制研究[J]. 中国癌症杂志, 2023, 33(3): 250-259.
[15]	曹晓珊, 丛斌斌. 三阳性乳腺癌内分泌治疗联合靶向治疗的研究进展[J]. 中国癌症杂志, 2023, 33(3): 288-292.